In pancreatic cancer, the overexpression of this pathway has been observed in concert with a decrease in PTEN expression in 25–70% of cases [27], and recently, many small-molecule anticancer agents have been developed to regulate autophagy and apoptosis associated with pancreatic cancer treatment targeting the PI3K/Akt/mTOR pathway [28]. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.